retatrutide nejm 2023 obesity trial ly3437943 This week's most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist for — A Phase 2 https://t.co/jNL1GNnHPT #Endocrinology Eli Lilly infiltrates anti-obesity market

Overall, as metabolic impairments and mitochondrial dysfunction are key drivers of AD pathology, exercise-mediated hepatokine regulation offers a viable strategy for preventing or slowing AD progression

PLoS ONE 9 , e92286 (2014)

These medications potently and selectively inhibit the enzymatic activity of DPP-4, enhancing the effectiveness of GLP-1 and glucose-dependent insulinotropic polypeptide (GIP), which are the primary incretins (endogenous glucoregulatory peptides, [39,40,41])

Intestinal mucosal microbial activity was found to be decreased in mice with diarrhea induced by a high-fat and high-protein diet (Zhou et al., 2023)